Catalyst Wire Dossier Catalyst Wire Dossier

Leronlimab

leronlimab · CytoDyn, Inc.
Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for Leronlimab, covering 2022-04-15 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

See pricing